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lishment of latency, as the cellular transcriptional state inﬂuences both
HIV transcription driven by its promoter located in the long terminal re-
gion (LTR) and reactivation from latency. Inhibitors that target the in-
teraction between integrase and LEDGF are variously termed non-
catalytic integrase inhibitors (NCINIs), allosteric inhibitors (ALLINIs),
or LEDGF inhibitors (LEDGINs). The molecular mechanisms by whichHIV DNA integration is essential for the persistence of HIV infection
and, to date, represents an insurmountable obstacle to an HIV cure. By
contrast, drugs that block the NS5B polymerase enzyme of HCV for
only 12weeks can frequently cure HCV infection because no integration
step is involved in theHCV replication cycle. Although inhibitors of each
of HIV reverse transcriptase, protease, and integrase have been success-
fully used to treat HIV infection, none of these are able to reverse the
persistence of integrated DNA copies of the viral genome. Hence, viral
loads typically rebound rapidly after treatment interruption due to acti-
vation and expression of the viral genome from latently infected cells
within the viral reservoir (Chun and Fauci, 2012).
Early initiation of antiretroviral therapy remains the only way to
limit the size of theHIV reservoir and, thus far, several interventions, in-
cluding treatment intensiﬁcation with the integrase strand transfer in-
hibitor (INSTI) raltegravir, have failed to achieve diminution of the
reservoir. Strategies that have been developed to eradicate HIV include
a “Shock and Kill” approach, whereby latently infected cells are activat-
ed and then killed by antiretroviral drugs (ARVs), stimulation by Toll-
like receptors, and the use of neutralizing or cytotoxic T lymphocyte-
speciﬁc antibodies (Spivak and Planelles, 2016). Alternative approaches
propose to push the virus into latency by using Tat inhibitors that limit
HIV post-latency reactivation (Mousseau et al., 2015).
Other HIV inhibitors have been developed that target the interaction
between the viral integrase and the cellular transcription factor lens ep-
ithelium-derived growth factor (LEDGF) (Christ et al., 2010). The ratio-
nale is that LEDGF can increase the efﬁciency of HIV integration while
also being necessary for HIV to integrate preferentially within transcrip-
tionally active genomic regions (Ciufﬁ et al., 2005). In cells depleted of
LEDGF, HIV integration sites were enriched in GC-rich genomic regions
andwere less frequent in actively transcribed regions thanwhen LEDGF
was present (Ciufﬁ et al., 2005). Of course, integration withinom.2016.04.039.
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LEDGINs inhibit HIV replication are not completely understood and
some LEDGINs can inhibit HIV post-integration events more efﬁciently
than integrase activity itself.
In this issue of EBioMedicine, Vranckx and colleagues show that a
LEDGIN termed CX014442 speciﬁcally alters HIV-1 genomic integration
in a manner that is similar to that associated with LEDGF depletion
(Ciufﬁ et al., 2005; Vranckx et al., 2016). The authors carefully character-
ized HIV integration sites in the presence of various concentrations of
CX014442 and found that this compound caused a dose-dependent
shift that now favored GC-rich regions for integration instead of actively
transcribed genomic regions (Vranckx et al., 2016). However, the pref-
erential DNA sequences targeted for integration did not change, and
Vranckx et al. veriﬁed that CX014442 did not favor HIV integration
within genomic regions that are identiﬁed as unsafe integration sites
(Vranckx et al., 2016), consistent with the notion that HIV integration
does not result in cellular transformation, although HIV integration at
sites close to genes involved in cellular survival has been linked to cellu-
lar clonal expansion without oncogenesis (Ikeda et al., 2007;Wagner et
al., 2014; Maldarelli et al., 2014). The authors further showed that inte-
gration events, in the presence of CX014442, were more likely to be lo-
calized deeper within the cellular nucleus (Vranckx et al., 2016),
consistent with a similar effect of LEDGF knockdown (Marini et al.,
2015). The use of the INSTI raltegravir or a catalytically inactive form
of integrase had similar effects (Marini et al., 2015).
Most remarkably, using an in vitro latencymodelwith a dual-report-
er virus, the scientists showed that post-latency reactivation was also
inhibited in the presence of CX014442. Accordingly, they argue that
LEDGINs may target HIV integration within genomic regions that are
less favorable for reactivation than those that are targeted in the pres-
ence of a functional integrase–LEDGF interaction. In support of this,
the authors also showed that latent infection in LEDGF-depleted cells
is less susceptible to reactivation by various latency reversing agents in-
cluding a combination of the protein kinase C activator prostratin to-
gether with SAHA, a histone deacetylase inhibitor. This is important as
latency reversing agents are being actively investigated as part of the
“Shock and Kill” cure strategy. The authors conclude that LEDGINs
may help reduce the portion of the HIV reservoir that is susceptible tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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treatment strategies aimed at reducing the size of the reservoir. One ca-
veat may be that the use of INSTIs or reverse transcriptase inhibitors
may actually be more beneﬁcial during early treatment, since the
LEDGINs may, in fact, be most active post-integrationally. Further re-
search is needed to better understand the molecular mechanism(s)
whereby LEDGINs inhibit HIV replication and to better distinguish be-
tween their anti-integrase versus post-integration effects. In addition,
CX014442 also seemed to be effective at different concentrations in dif-
ferent cell types and this also needs to be further studied as should the
reasons for the LEDGIN- and raltegravir-dependent relocalization of in-
tegration to sites that are deeperwithin the nucleus. And, clariﬁcation is
needed to understand the link between integration sites within speciﬁc
genomic regions and susceptibility to latency reversal. The use of non-
human primate and/or humanized mouse models might also provide
much needed insights in regard to the possible role of LEDGINs in HIV
eradication.
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